Inegy

Simvastatin and ezetimibe, the active ingredient in Inegy, is a HMG‑CoA reductase inhibitor; cholesterol absorption inhibitor presented as a tablet for oral use. It lowers elevated cholesterol levels in adults with hypercholesterolemia or mixed dyslipidemia.

GNH USA supplies Inegy as a licensed, GDP-compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Inegy is indicated for the management of lipid disorders, targeting elevated cholesterol and triglyceride levels.

Hypercholesterolemia: reduces LDL‑cholesterol and total cholesterol levels. Mixed dyslipidemia: lowers LDL‑cholesterol while modestly decreasing triglycerides and raising HDL‑cholesterol. Primary hyperlipidemia: helps achieve target lipid profiles as part of a therapeutic regimen.

Inegy may cause a range of adverse reactions, varying from mild to serious.

Common Side Effects: - Headache - Myalgia - Abdominal pain - Diarrhea

Serious or Rare Side Effects: - Myopathy or rhabdomyolysis - Elevated liver enzymes (hepatotoxicity) - Severe allergic reactions such as angioedema

Before initiating therapy, consider the following precautions. - Monitor liver function: obtain baseline hepatic enzymes and repeat periodically. - Assess muscle symptoms: discontinue if unexplained muscle pain or weakness occurs. - Avoid use in active liver disease: contraindicated in patients with persistent hepatic impairment. - Adjust dose in renal impairment: evaluate renal function and modify therapy as needed. - Review concomitant medications: avoid drugs that inhibit CYP3A4 or increase statin exposure. - Store at ambient temperature: keep in the original pack, protect from moisture.

Inegy can interact with several medicines; awareness of interaction severity is essential.

Major Interactions (Avoid): - Strong CYP3A4 inhibitors (e.g., itraconazole, clarithromycin): increase simvastatin exposure and risk of myopathy. - Gemfibrozil: combined use can raise risk of muscle toxicity. - Cyclosporine: elevates statin levels, increasing rhabdomyolysis risk.

Moderate Interactions (Monitor Closely): - Warfarin: may enhance anticoagulant effect; monitor INR. - Niacin: may increase risk of liver dysfunction. - Antacids containing aluminum or magnesium: may reduce ezetimibe absorption.